Fresh analysis suggests that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who stop conventional lifestyle programs.
Findings released in a leading medical journal demonstrates that while obese people can lose substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such medications must be cognizant of the danger of rapid rebound weight gain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to starting weight within about 18 months.
Analyzing Treatments
The study, which reviewed 37 of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with older methods.
Scientists note that people who shed pounds through lifestyle changes alone typically see a less rapid weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Doctors believe the way of the drugs explains the accelerated rebound.
The injections mimic a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to appetite is uncontrolled, making overeating much more probable."
A Lifelong Condition?
The NHS advise the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, given the high risk of weight regain, the treatment might need to be life-long.
This view is echoed by pharmaceutical companies, who state that the results "highlight the persistent character of obesity," akin to managing conditions like hypertension.
Patient Accounts
Individuals who have stopped the medication describe a sudden resurgence of hunger.
"It was like a trigger activating and I was suddenly ravenous," described one woman.
The struggle is compounded if patients have not developed lasting dietary or behavioural modifications during treatment.
Significant Use
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among women compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, experts stress that while these medications are effective tools for weight loss, they are not a standalone cure and long-term success likely depends on ongoing behavioural changes.
